Abstract Body

Zoledronic acid (ZOL) 5mg annually was more effective than switching tenofovir disoproxil fumarate (TDF) at increasing bone mineral density (BMD) over 24 months in HIV-infected, osteopenic adults. The relative effects of ZOL vs. TDF-switching on plasma bone turnover markers (BTMs) are unknown. Further, it is not clear if TDF causes bone loss by reducing bone formation or increasing bone resorption.

We measured plasma levels of C-terminal telopeptide of type 1 collagen (CTX; a marker of bone resorption) and procollagen type 1 N propeptide (P1NP; a marker of bone formation) in participants in the randomised trial comparing annual ZOL 5mg with TDF switching over 24 months. Percent changes in CTX and P1NP were compared in the per-protocol population at Months 1, 3, 6, 12 and 24 with a Wilcoxon test and over all follow-up with Generalised Estimating Equations (GEE). We also determined whether BTM changes at Month 3 predicted hip and spine BMD changes (Pearson’s correlation coefficient).

Plasma samples were available for 42 of 44 participants (95%) in the TDF switch group and 41 of 42 participants (98%) in the ZOL group. Median percent decreases in both BTMs were significantly greater with ZOL than with TDF-switching through Month 24 by GEE and at each time point (all p<0.001; see Figure 1). For example, at Month 12 the median (IQR) changes for ZOL vs. TDF-switch groups for P1NP were -53.5% (IQR -40.5%, -63.3%) and -25.4% (-9.8%, -41.0%), respectively, and for CTX were -49.7% (-30.7%, -62.7%) and -19.1% (+13.4%, -41.6%), respectively. Combining both groups, decreases in P1NP at M3 were more strongly correlated with decreases in BMD at M24 at the spine (r2=-0.44; p<0.001) and hip (r2=-0.45; p<0.001) than were the respective decreases in CTX (spine r2=-0.36; p=0.001, and hip r2=-0.23; p=0.051). In patients who switched TDF, the decrease at Month 1 in CTX was -19.7% (IQR -39.2%, +6.1%) whereas the change for P1NP was only -4.0% (–15.4%, +7.1%).

ZOL resulted in larger decreases in bone turnover than did TDF-switching. The decrease in bone turnover in the TDF-switch group suggests that TDF reduces BMD by increasing bone turnover. Early changes in P1NP predicted BMD changes at 24 months with both ZOL and TDF-switching.